SRAMF (Sisram Medical) Beta: -0.9275 (As of Jun. 27, 2026)


SRAMF Sisram Medical Ltd SRAMF
60 GF Score
Price $0.44
GF Value $0.95
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sisram Medical Beta?

Sisram Medical SRAMF 60 Beta is -0.9275 as of Jun. 27, 2026. GuruFocus rates SRAMF with a GF Score™ of 60/100 and a GF Value™ of $0.95 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Sisram Medical's Beta is -0.9275.


Sisram Medical  (OTCPK:SRAMF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Sisram Medical Beta Related Terms


Sisram Medical Beta Historical Data

* Premium members only.

The historical data trend for Sisram Medical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sisram Medical Beta Chart

Sisram Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.39 0.00 -0.36

Sisram Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.39 1.33 0.00 -0.01 -0.36

SRAMF vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, Sisram Medical's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sisram Medical Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's Beta distribution charts can be found below:

* The bar in red indicates where Sisram Medical's Beta falls into.


SRAMF
60GF Score
Sisram Medical Ltd SRAMF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sisram Medical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.9275 mean?
Sisram Medical (SRAMF) has a Beta of -0.9275 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sisram Medical and its competitors.
Is Sisram Medical's Beta too high?
Sisram Medical's current Beta is -0.9275. Overall, Sisram Medical has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's Beta compare to ABT and SYK?
Sisram Medical's Beta of -0.9275 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sisram Medical and its competitors. Sisram Medical's current Beta is -0.9275. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.95, compared to a current price of $0.44 — trading 53.9% below its estimated fair value. The current Beta is -0.9275. Sisram Medical's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current Beta is -0.9275 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sisram Medical (SRAMF) Overvalued in 2026?

Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued. The current stock price of $0.44 is trading 53.9% below its estimated GF Value™ of $0.95. GuruFocus considers Sisram Medical to be Significantly Undervalued.

Key valuation signals for SRAMF:

  • Beta: -0.9275
  • GF Value™: $0.95 vs. price of $0.44 (53.9% below fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sisram Medical Business Description

Other Exchanges 01696:Hong Kong
Address HaHarash Street 18, Ofek Building 15, Industrial Park, Caesarea, ISR, 3079895
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
60GF Score

Get the complete analysis for SRAMF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price
$0.95
GF Value